<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479154</url>
  </required_header>
  <id_info>
    <org_study_id>070160</org_study_id>
    <secondary_id>07-N-0160</secondary_id>
    <nct_id>NCT00479154</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin to Treat Restless Legs Syndrome</brief_title>
  <official_title>Pilot Study of Botulinum Toxin Type A for the Treatment of Restless Legs Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether botulinum toxin (Botox) may relieve the uncomfortable sensations
      patients with restless legs syndrome (RLS) experience. RLS is a common movement disorder that
      causes sensory discomfort and restlessness, most often in the legs, which improves with
      movement. Although medications are available to treat the disorder, many people experience
      side effects that prevent them from continuing on the medication. The Food and Drug
      Administration has approved Botox for other movement disorders and for some cosmetic uses.

      People 18 years of age or older with moderate to severe RLS who have been taking RLS
      medications for more than 6 weeks before entering the study may be eligible to participate.
      Candidates are screened with a medical history, physical and neurological examinations, blood
      tests and, for women who can become pregnant, a urine pregnancy test.

      Participants are randomly assigned to receive injections of either Botox or placebo (salt
      water) into up to nine areas of the legs. The correct location of the muscles to be injected
      is determined by electromyography (EMG), a test that measures the electrical activity of
      muscles. For surface EMG, electrodes (small metal disks) are filled with a conductive gel and
      taped to the skin. Needle EMG involves inserting a needle into a muscle. Both methods are
      used in this study.

      At 2 and 4 weeks after the injections, subjects are interviewed by telephone and asked to
      describe their symptoms, side effects and any improvement they may have noticed. After 12
      weeks they return to NIH for injections with the alternate compound; that is, those who
      received Botox previously are given placebo for the second set of injections, and vice-versa.
      Subjects are again contacted by telephone 2 and 4 weeks after the injections to report their
      symptoms, side effects and benefits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE:

      To evaluate the efficacy of botulinum toxin type A, (BoNT) for the treatment of primary
      Restless legs syndrome (RLS). We hypothesize that BoNT will be effective at decreasing the
      deep sensory discomfort of RLS.

      STUDY POPULATION:

      This protocol is a proof of principle double-blind randomized placebo-BoNT crossover
      outpatient pilot study of 6 patients diagnosed with moderate to very severe primary RLS.

      DESIGN:

      All subjects will be evaluated at the NIH Clinical Center by a study investigator to
      determine eligibility for participation in this protocol. We will obtain a complete medical
      history, and perform a neurological examination, along with laboratory screening studies.
      Subjects eligible to participate will receive baseline ratings using the Restless Legs Rating
      Scale (RLS-RS). Subjects will then be randomized to receive electromyography (EMG)-guided
      injections of up to 90 units of BoNT or an equivalent volume of saline in each lower
      extremity, in symptomatic muscles. Subjects will then receive follow up ratings at week 2 and
      4 following each injection. Twelve weeks after receiving the first injection, subjects will
      crossover to receive the alternative compound with similar follow up ratings.

      OUTCOME MEASURES:

      The primary outcome measure will be mean change from baseline at 4 weeks post-injection on
      the RLS-RS for placebo and BoNT, while the other pre specified outcomes will evaluate patient
      reported Clinical Global Impression of Change (CGI-C) scores for each group, duration of
      effect, and adverse events. Only descriptive statistics will be performed on this limited
      data sample.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Restless Legs Syndrome Rating Scale</measure>
    <time_frame>Week 2 and Week 4 for each intervention (vs. baseline)</time_frame>
    <description>Primary outcome measure will be the mean change from baseline in RLS scale at week 2 following placebo/BTX injections. Scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of onabotulinumtoxinA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin A</intervention_name>
    <description>Maximum dose of 90 units/leg was injected.</description>
    <arm_group_label>Botulinum Toxin A</arm_group_label>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <other_name>onabotulinum toxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Age 18 or older.

          -  Diagnosed with primary RLS based on presence of a characteristic clinical history and
             the International restless legs syndrome study group (IRLSSG) diagnostic criteria.

          -  A minimum score of 11 on the RLS rating scale (this is equivalent to a minimum rating
             of moderate severity).

          -  If subjects are on medications for RLS, the medication regimen must be stabilized for
             greater than 6 weeks prior to entering the study.

        EXCLUSION CRITERIA:

          -  Subjects with any abnormal findings on neurological exam.

          -  Subjects with a dermatologic disorder that precludes injections in the legs.

          -  Subjects with a positive urine pregnancy test.

          -  Subjects without the capacity to give informed consent.

          -  Subjects taking aminoglycosides, chloroquine, clindamycin, hydroxychloroquine,
             magnesium sulfate, quinidine, or an anticoagulant.

          -  Subjects with abnormal clinical chemistry, hematology or urine drug screen by
             laboratory testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatta Nahab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NINDS/NIH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, SÃ¼dhof TC, Niemann H, Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993 Sep 9;365(6442):160-3.</citation>
    <PMID>8103915</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2007</study_first_submitted>
  <study_first_submitted_qc>May 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <results_first_submitted>March 14, 2011</results_first_submitted>
  <results_first_submitted_qc>April 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2012</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Fatta Nahab</investigator_full_name>
    <investigator_title>Assistant Clinical Investigator</investigator_title>
  </responsible_party>
  <keyword>Restless Leg Syndrome</keyword>
  <keyword>Botulinum Toxin</keyword>
  <keyword>RLS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Then Botulinum Toxin</title>
          <description>Injection into set of leg muscles with Placebo followed by crossover to Botulinum Toxin (90 mU per leg) at week 6.</description>
        </group>
        <group group_id="P2">
          <title>Botulinum Toxin Then Placebo</title>
          <description>Injection of Botulinum Toxin (90 mU per leg) followed by crossover to placebo at week 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Then Botulinum Toxin</title>
          <description>Injection into set of leg muscles with Placebo followed by crossover to Botulinum Toxin (90 mU per leg) at week 6.</description>
        </group>
        <group group_id="B2">
          <title>Botulinum Toxin Then Placebo</title>
          <description>Injection of Botulinum Toxin (90 mU per leg) followed by crossover to placebo at week 6.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" spread="11.8"/>
                    <measurement group_id="B2" value="61.7" spread="2.5"/>
                    <measurement group_id="B3" value="57.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Restless Legs Syndrome Rating Scale</title>
        <description>Primary outcome measure will be the mean change from baseline in RLS scale at week 2 following placebo/BTX injections. Scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40).</description>
        <time_frame>Week 2 and Week 4 for each intervention (vs. baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Injection into set of leg muscles with Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin</title>
            <description>Injection of Botulinum Toxin (90 mU per leg).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Restless Legs Syndrome Rating Scale</title>
          <description>Primary outcome measure will be the mean change from baseline in RLS scale at week 2 following placebo/BTX injections. Scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40).</description>
          <units>RLS Rating Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="5.1"/>
                    <measurement group_id="O2" value="-1.0" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="5.9"/>
                    <measurement group_id="O2" value="-5.0" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Then Botulinum Toxin</title>
          <description>Injection into set of leg muscles with Placebo followed by crossover to Botulinum Toxin (90 mU per leg) at week 6.</description>
        </group>
        <group group_id="E2">
          <title>Botulinum Toxin Then Placebo</title>
          <description>Injection of Botulinum Toxin (90 mU per leg) followed by crossover to placebo at week 6.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fatta Nahab</name_or_title>
      <organization>NINDS/NIH</organization>
      <phone>301-496-9526</phone>
      <email>nahabf@ninds.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

